On July 10, Hansoh Pharmaceutical rose 3.08% in regular trading, trading at 32.24 HKD/share, with turnover of approximately 69.54 million HKD.
On the news front, the innovative drug sector rallied broadly as payment reform catalysts continued to unfold. The National Healthcare Security Administration previously published the medical insurance directory preliminary review results, with the dual-track system of basic medical insurance plus commercial insurance entering substantive negotiations. Supporting mechanisms including a pre-filing system and an 8-year price protection period have been implemented simultaneously, providing stable policy expectations for innovative drug commercialization.
At the company level, pipeline catalysts have been released in quick succession. The independently developed Class 1 new drug HS-20136-2 injection received two clinical trial approvals from the NMPA for type 2 diabetes and weight management. Previously, the weight-loss drug olatorepatide and HS-10568 injection NDAs were both accepted, accelerating the commercialization process. Sector linkage was significant, with ASYMCHEM up 5.55%, CSPC Pharma up 3.83%, Hengrui Pharma up 3.59%, and SBP Group up 3.4%.
(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)
